EFX
47
4
LEN
38
-3
GT
41
-13
PEP
45
-2
LUV
62
-9
HSY
37
2
KMI
63
6
T
35
2
BAX
42
-5
MCK
66
6
MCHP
50
-2
WY
37
-2
SE
49
2
RCL
62
-4
HUM
33
-3
DG
68
13
BMY
73
5
IVZ
68
15
NWL
57
-3
ADP
61
-3
EFX
47
4
LEN
38
-3
GT
41
-13
PEP
45
-2
LUV
62
-9
HSY
37
2
KMI
63
6
T
35
2
BAX
42
-5
MCK
66
6
MCHP
50
-2
WY
37
-2
SE
49
2
RCL
62
-4
HUM
33
-3
DG
68
13
BMY
73
5
IVZ
68
15
NWL
57
-3
ADP
61
-3
Financhill
Back

Allogene Therapeutics, Inc. 10K Form

Buy
58

ALLO
Allogene Therapeutics, Inc.

Last Price:
$1.45
Seasonality Move:
-16.51%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive ALLO News And Ratings

See the #1 stock for the next 7 days that we like better than ALLO

ALLO Financial Statistics

Sales & Book Value

Annual Sales: $22K
Cash Flow: $-29.9M
Price / Cash Flow: 0
Annual Sales: $1.41
Price / Book: 1.03

Profitability

EPS (TTM): -0.98110
Net Income (TTM): $-212M
Gross Margin: $-13.6M
Return on Equity: -54.89%
Return on Assets: -41.47%

Allogene Therapeutics, Inc. Earnings Forecast

Key Allogene Therapeutics, Inc. Financial Ratios

  • The Gross Profit Margin over the past 4 years for ALLO is -61,895.45%.
  • The Selling, General & Administrative Expenses for ALLO have been equal to 296,386.36% of Gross Profit Margin.
  • The Research & Development expenses have been 812,090.91% of Revenue.
  • The Net Earning history of ALLO is -1,170,863.64% of Total Revenues.
  • Per Share Earnings over the last 7 years have been positive in 4 years.

Allogene Therapeutics, Inc. Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: ALLO
CUSIP: 019770
Website: allogene.com

Debt

Debt-to-Equity Ratio: 0.27
Current Ratio: 8.19
Quick Ratio: 7.92

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

ALLO Technical Analysis vs Fundamental Analysis

Buy
58
Allogene Therapeutics, Inc. (ALLO) is a Buy

Is Allogene Therapeutics, Inc. a Buy or a Sell?